Stephen H. Friend, MD/PhD
President, Co-Founder and Director of Sage Bionetworks
Dr. Friend is the President of Sage Bionetworks. He was previously Senior Vice President and Franchise Head for Oncology Research at Merck & Co., Inc. where he led Merck’s Basic Cancer Research efforts. He led the Advanced Technologies and Oncology groups to firmly establish molecular profiling activities throughout Merck’s laboratories around the world, as well as to coordinate oncology programs from Basic Research through phase IIA clinical trials. Prior to joining Merck, Dr. Friend along with Dr. Leland Hartwell founded and co-led the Fred Hutchinson Cancer Research Center’s “Seattle Project”, an advanced institute for drug discovery. While there Drs. Friend and Hartwell developed a method for examining large patterns of genes that led them to co-found Rosetta Inpharmatics in 1997. Dr. Friend has also held faculty positions at Harvard Medical School from 1987 to 1995 and at Massachusetts General Hospital from 1990 to 1995. He received his B.A. in philosophy, his Ph.D. in chemistry and his M.D. from Indiana University. Dr. Friend was named an Ashoka Fellow for his work at Sage Bionetworks.
Diane Gary, MBA
Diane Gary has responsibility for the organization’s finance, human resources, grant management and general business activities. Ms. Gary has held similar roles in other early-stage companies, including Rosetta Inpharmatics through the initial funding, IPO and acquisition by Merck & Co. Inc., and KidStar Interactive Media. Most recently, she was HR Director for Merck’s Seattle and San Francisco research sites. Prior experience also includes work with a hospital foundation, with a nonprofit healthcare association, and on the board of the Country Doctor Community Health Centers. Ms. Gary holds an MBA degree from the University of Washington.
Michael Kellen leads the technology platforms and services team at Sage Bionetworks. Since 2009, the team has supported open projects and challenges in the collaborative analysis of human health data through the development of the Synapse platform, and by providing support with data hosting, curation, and analysis. The team is now expanding scope into the collection of rich human phenotypic data though the development of the Bridge platform. Michael has over 10 years experience developing software for academic and corporate users in the life sciences, and has brought several award-winning products to market in this space covering simulation, data capture and analysis workflow, data integration, and team collaboration. Prior to Sage, Michael held a variety of positions with Teranode corporation since joining as the company’s first employee in 2002, covering product development, field consulting, product management, and development management. Michael completed a doctorate in bioengineering at the University of Washington in 2002 with a focus in computational biology where he also helped develop scientific modeling and simulation technology subsequently licensed by Teranode.
Lara Mangravite, PhD
Lara Mangravite, PhD is Director of the Systems Biology research group. This team focuses on application of systems biology approaches to advance understanding of disease biology and treatment outcomes with the overriding goal of improving clinical care. As part of these efforts, the team is working in parallel to pilot new approaches to scientific process that use open systems to enable community-based collaborative research efforts to solve complex problems in a collective manner that is more efficient and effective than standard research approaches. Lara’s previous research experience has focused on the identification of prognostic biomarkers through the analysis of genomic and molecular profiles derived from both clinical trials and experimental model systems. Dr. Mangravite obtained a BS in Physics from the Pennsylvania State University and a PhD in Pharmaceutical Chemistry from the University of California, San Francisco. She completed a postdoctoral fellowship in cardiovascular pharmacogenomics at the Children’s Hospital Oakland Research Institute.
Adam Margolin, PhD
Dr. Margolin directs the Computational Biology team at Sage Bionetworks, overseeing the development of novel computational methods for predicting disease-related phenotypes; developing large-scale data processing and sharing tools; and leading several consortium-based projects to leverage cloud-enabled computing technologies for collaborative analysis across a distributed network of investigators. Dr. Margolin is a pioneer in computational approaches for inferring cellular regulatory networks, and developing predictive models linking alterations in cellular networks to clinical cancer phenotypes. Dr. Margolin received his B.S. from the Wharton School of Business at the University of Pennsylvania, his M.S. in Computer Science from the University of Pennsylvania, and his Ph.D. from Columbia University. Prior to joining Sage Bionetworks, Dr. Margolin initiated and led an effort at the Broad Institute of Harvard and MIT to leverage large-scale cancer genomics datasets to infer genotype-specific therapeutics in human tumors. This work led to numerous high-impact demonstrations of the ability to infer clinically relevant tumor biomarkers. Dr. Margolin’s group at Sage Bionetworks is currently working to scale-up and develop sophisticated machine learning approaches to integrate diverse data-types into multi-scale, network-based predictive models of cancer phenotypes.
John Wilbanks is the Chief Commons Officer at Sage Bionetworks and a Senior Fellow in Entrepreneurship at the Ewing Marion Kauffman Foundation. He has worked at Harvard’s Berkman Center for Internet & Society, the World Wide Web Consortium, the US House of Representatives, and Creative Commons. John is a past affiliate of MIT’s Project on Mathematics and Computation and also started a bioinformatics company called Incellico, which is now part of Selventa. He sits on the Advisory Boards for Boundless Learning, Genomic Arts, Curious, GenoSpace, Patients Like Me, and Genomera, and is Special Advisor on the Research Commons to the University of California San Francisco’s Clinical Translational Science Institute. John holds a degree in Philosophy from Tulane and studied modern letters at the Sorbonne.